Step therapy: Where do we stand? – Retina Specialist
Answers to questions that linger since Medicare Advantage organizations started implementation for anti-VEGF treatments.
In August 2018, the Centers for Medicare and Medicaid Services announced plans to institute step therapy for some Medicare beneficiaries enrolled in Medicare replacement plans, also known as Medicare Advantage plans. Historically, step therapy was only used to control costs within private insurance plans. CMS touted this step therapy rule as a cost-saving measure with little downside to most patients.
This article was published in Retina Specialist, which is written by Ellen R. Adams, MBA. To view the entire article in Retina Specialist, click on the link below: